Good MorningThe rebound in equities faltered on Monday and for good reasons. Not only is there a key read on inflation due out at the end of the week but the price of oil is rebounding. The price for WTI gained more than 2.5% at the height of the session to top $111.75 on its way back to the short-term moving average at $113.37. If the market gets above that level we see the price of WTI moving up to retest and possibly set a new all-time high and drive inflation to new levels. In regards to inflation, the PCE price index is due out on Thursday and it is expected to be hot. The core PCE is expected to accelerate a tenth to 0.4% on a month-to-month basis and drive the YOY gain to over 5.0% to put even more pressure on the FOMC to act.
The latest read on the FOMC is that a 75 basis point interest rate hike will come in July and another one is likely in August. This will put rates at 3.0% to 3.25% by the middle of summer versus the end of the year as was predicted just a month ago. If the PCE data is hotter than expected it is likely the FOMC will increases rates at an even more aggressive pace and potentially throw the economy into a lengthy recession. Featured:
Our #1 Small-Cap Stock for May (BehindtheMarkets) |
Politics | | British Prime Minister Boris Johnson’s bid to rip up parts of the post-Brexit trade deal he signed with the European Union has cleared its first hurdle in Parliament, despite warnings from opponents that the move is illegal.
Lawmakers voted 295 to 221 late Monday to give initial appr... Read the Full Story >> |
|
From Our PartnersThis trader trades only ONE stock — and profited through the 2000, 2008, and 2020 crashes. | | Learn More |
|
Markets | | Global stocks were mostly higher Tuesday after a wobbly day on Wall Street as markets cooled off following a rare winning week.
Oil prices pushed higher and U.S. futures also advanced.
As they wrapped up a summit in Elmau, Germany, Group of Seven leaders were finalizi... Read the Full Story >> |
|
Markets | | Digital operations management platform PagerDuty, Inc. (NYSE: PD) stock has outperformed the technology bear market down just (-18%) on the year. The digital ecosystem management platform enables enterprises to manage and analyze digital applications in real-time using artificial intelligence (AI) a... Read the Full Story >> |
|
From Our PartnersThis hidden income strategy was just leaked and it can be yours now. It goes in depth about how you can start off with a small account and turn that into your own weekly paycheck. Learn how you can GAIN that extra advantage over what others aren't doing. | Click here to get this secret |
|
Markets | | Cybersecurity provider SentinelOne (NYSE: S) stock has fallen (-44%) year-to-date in the technology bear market despite its triple digit growth. The cloud-based cybersecurity provider provides artificial intelligence (AI) based protection for endpoints, cloud, and identity, which are areas offering ... Read the Full Story >> |
|
Markets | | Through June 24th, all but 16 of the popular benchmark’s names were in the red for 2022. At the other end of the spectrum is an unlikely collection of stocks that have boldly bucked the market trend. The upside in these three Nasdaq-100 stocks has only begun. Read the Full Story >> |
|
From Our PartnersThanks to a little-known IRS exemption, you can now shift a portion of your 401(k)/IRA into physical gold - tax-free.
And to help you take action, I wrote a NEW 32-page Inflation Survival Plan that shows you how it works.
If you'd like a copy, I'll FedEx it to you right away at zero cost.
Inside, you'll see How to position yourself to possibly grow RICHER if the Dow tumbles in 2022
Tell me where to send your guide, and you're set | Click Here to Get Your FREE Inflation Survival Guide |
|
Markets | | Polestar (NYSE: PSNY) is a Swedish electric car maker, which is a part of the Volvo group. The company went public through a special purpose acquisition company (SPAC) with The Gores Guggenheim Group. Read the Full Story >> |
|
Politics | | The head of the European Central Bank says it will move gradually to combat soaring consumer prices with interest rate hikes in July and September but will keep its options open to “stamp out” inflation if it surges faster than expected Read the Full Story >> |
|
Politics | | The Group of Seven on Tuesday was wrapping up a summit intended to send a strong signal of long-term commitment to Ukraine's future, ensuring that Russia pays a higher price for its invasion while also attempting to alleviate a global hunger crisis and show unity against climate change.
... Read the Full Story >> |
|
Politics | | The Czech Republic has signed deals with Westinghouse Electric Co. and France’s Framatome to deliver fuel supplies for a nuclear power plant, reducing the country’s dependence on Russia.
The Czech state-controlled power company CEZ said on Tuesday that Pennsylvania-based Westinghouse ... Read the Full Story >> |
|
Markets | | H.B. Fuller has proven to be inflation-proof if nothing else. The company manufactures adhesive chemicals for 3 end markets and the demand is high despite a series of pricing increases. The pricing increases are coupled with volume growth as well, not something we’re seeing in most reports, and has revenue and earnings at record levels. Read the Full Story >> |
|
Tuesday's Early Bird Stock Of The Day Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. | View Today's Stock Pick |
|